Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 and SMAD3 signaling, showed promising results in a phase 2 study.
Fenaux, P., Platzbecker, U., Mufti, G.j., Garcia-Manero, G., Buckstein, R., Santini, V., et al. (2020). Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. THE NEW ENGLAND JOURNAL OF MEDICINE, 382(2), 140-151 [10.1056/NEJMoa1908892].
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Voso, Maria-Teresa;
2020-01-01
Abstract
Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 and SMAD3 signaling, showed promising results in a phase 2 study.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Fenaux NEJM 2020.pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
247.28 kB
Formato
Adobe PDF
|
247.28 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
